Structurally, it shares 94% sequence homology with human GLP-1 but includes two critical modifications: the substitution of amino acids to prevent enzymatic degradation by Dipeptidyl Peptidase-4 (DPP-4), and the addition of a C-18 fatty di-acid side chain
Even then, its usually not Ozempic that Medicaid will cover, but a drug like Wegovy, which is a separate semaglutide drug thats FDA approved for weight management
Understanding Semaglutide Semaglutide, belonging to the class of GLP-1 agonists, stands out for its remarkable weight loss benefits, averaging around 15 to 20 percent in the long term
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP1 trial extension
It may be recommended by providers off-label to fulfill patient needs and address challenges associated with standard treatment protocols